Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study

PURPOSE: The primary objective of this study was to assess long-term safety with sublingual asenapine 2.5 or 5 mg twice daily (BID) in patients with schizophrenia. PATIENTS AND METHODS: Actively treated patients on asenapine 2.5 mg BID, asenapine 5 mg BID, or olanzapine 15 mg once daily (QD) who com...

Descripción completa

Detalles Bibliográficos
Autores principales: Durgam, Suresh, Landbloom, Ronald P, Mackle, Mary, Wu, Xiao, Mathews, Maju, Nasrallah, Henry A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546824/
https://www.ncbi.nlm.nih.gov/pubmed/28814871
http://dx.doi.org/10.2147/NDT.S130211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546824/
https://www.ncbi.nlm.nih.gov/pubmed/28814871
http://dx.doi.org/10.2147/NDT.S130211

Ejemplares similares